Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: Analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial

Journal of Rheumatology

Volumn 40, Issue 4, 2013, Pages 369-378

  Weinblatt, Michael E ^a   Kavanaugh, Arthur ^b   Genovese, Mark C ^c   Jones, David A ^d   Musser, Theresa K ^c   Grossbard, Elliott B ^e   Magilavy, Daniel B ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY   (United States)

^d ASTRAZENECA   (United Kingdom)

^e RIGEL PHARMACEUTICALS INC   (United States)

Author keywords

Fostamatinib; Health related quality of life; Patient reported outcomes; Randomized clinical trial; Rheumatoid arthritis

Indexed keywords

FOSTAMATINIB; METHOTREXATE; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SELF REPORT; SHORT FORM 36;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MOTOR ACTIVITY; OXAZINES; PAIN; PAIN MEASUREMENT; PROTEIN-TYROSINE KINASES; PYRIDINES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84875845688     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120923     Document Type: Article

References (27)

1. Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl. 1994 Sept;41:86-9.
2. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36:729-40.
3. Tugwell P, Boers M. Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. OMERACT Committee. J Rheumatol 1993;20:555-6.
4. Kalyoncu U, Dougados M, Daures JP, Gossec L. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2009;68:183-90.
5. Strand CV, Crawford B. Longterm treatment benefits are best reflected by patient reported outcomes. J Rheumatol 2007; 34:2317-9.
6. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2007;13 Suppl:S237-51.
7. Carr AJ. Margaret Holroyd Prize Essay. A patient-centred approach to evaluation and treatment in rheumatoid arthritis: the development of a clinical tool to measure patient-perceived handicap. Br J Rheumatol 1996;35:921-32.
8. Kwoh CK, Ibrahim SA. Rheumatology patient and physician concordance with respect to important health and symptom status outcomes. Arthritis Rheum 2001;45:372-7.
9. Gossec L, Dougados M, Rincheval N, Balanescu A, Boumpas DT, Canadelo S, et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: A EULAR initiative. Ann Rheum Dis 2009;68:1680-5.
10. Sanderson T, Morris M, Calnan M, Richards P, Hewlett S. What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set. Arthritis Care Res 2010;62:640-6.
11. Hewlett S, Carr M, Ryan S, Kirwan J, Richards P, Carr A, et al. Outcomes generated by patients with rheumatoid arthritis: how important are they? Musculoskeletal Care 2005;3:131-42.
12. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006;319:998-1008.
13. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303-12.
14. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
15. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
16. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
17. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005;32:811-9.
18. Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. J Rheumatol 2008;35:20-30.
19. Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010;70:121-45.
20. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
21. Ware JE Jr, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. User's manual for the SF-36v2™ health survey. 2nd ed. Lincoln, RI: QualityMetric Inc.; 2007.
22. Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics 2004;22 Suppl:27-38.
23. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 2008;67:1360-4.
24. Strand V, Burmester GR, Ogale S, Devenport J, John A, Emery P. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology 2012;51:1860-9.
25. Wolfe F, Michaud K. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Res Ther 2010;12:R35.
26. Strand V, Gajria K, Williams P, Barrett A, Fernandes A, Magrini F. Responsiveness of health-related quality-of-life measures in rheumatoid arthritis randomized controlled trials [abstract]. Arthritis Rheum 2011;63 Suppl:141.
27. Krishnan E, Tugwell P, Fries JF. Percentile benchmarks in patients with rheumatoid arthritis: Health Assessment Questionnaire as a quality indicator (QI). Arthritis Res Ther 2004;6:R505-13.